Bavarian initiates challenge study with RSV vaccine in 2018
Bavarian Nordic has updated its plans for the development of a vaccine against respiratory syncytial virus (RSV). The plans include a placebo-controlled challenge trial in the second half of 2018, which should lead to a pivotal phase III study.
BY MARTIN HAVTORN PETERSEN
After a thorough flop in the development of the prostate cancer vaccine Prostvac, Bavarian Nordic now turns to its experimental MVA-BN RSV-vaccine against respiratory syncytial virus (RSV).